Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 68.84M |
| Revenue (ttm) | 698,000 |
| Net Income (ttm) | -47.30M |
| Shares Out | 28.86M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,615 |
| Open | 2.390 |
| Previous Close | 2.390 |
| Day's Range | 2.340 - 2.415 |
| 52-Week Range | 1.900 - 4.210 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 10, 2025 |
About VTGN
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spra... [Read more]
Financial Performance
Financial StatementsNews
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s results from the PALISADE-3 and PALISADE-4 studies, using fasedienol for the treatment of patients with Social Anxiety Disorder, expected in 2025. Fifth proof-of-concept ...
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh ...
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected b...
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positiv...
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollm...
Vistagen to Present at the Stifel 2024 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,...
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Princ...
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,...
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,...
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,...
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one...
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to ...
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and comm...
Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince...
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and com...
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and com...